Machinery / Industrial Parts & Tools

"In the post-epidemic era, hierarchical diagnosis and treatment and the sinking of medical resources have become a fait accompli, and the configuration and procurement of medical equipment is one of the key tasks. The basic requirements are: equipment vacancies must be filled as soon as possible, and old and backward updated in time. ；

In this process, domestic medical equipment has become the first choice of many provinces. The scene of domestic brands and international giants "fighting bayonet" has reached an irreparable situation, and the determination to compete has become clear. "

01

The total purchase amount is about 4 million

On May 27, the Hengyang Municipal Medical Insurance Bureau’s "centralized procurement of consumables (drugs) related to the treatment of end-stage renal disease" triggered a heated discussion in the industry. According to the inquiry of Cyblan Instruments, a pharmaceutical company in Hunan was commissioned by the Hengyang Medical and Medical Security Bureau , To carry out centralized procurement of relevant medical consumables, and the agreed procurement quantity is determined by the cumulative calculation of the actual demand reported by each medical institution.

The document pointed out that among the agreed procurement volume, selected domestic products accounted for more than 90%, and selected imported products accounted for less than 10%. The selected products are evenly allocated the corresponding agreed purchase amount.

This centralized procurement starts from the implementation date, a procurement cycle is 24 months, and the agreement is signed on the basis of the procurement year. If the agreed purchase quantity is completed in advance during the purchase cycle, the excess part of the selected companies will still guarantee the supply at the selected price until the expiration of the purchase cycle. During the procurement cycle, if the state organizes centralized procurement and other related policy adjustments, it will be implemented in accordance with the relevant provisions of the latest policy.

In order to reduce product prices to the greatest extent and reduce the capital costs of distribution companies and manufacturers, the proposed payment settlement period is 90 days. The purchase and sale agreement must truthfully reflect the actual supply price and purchase volume, and the medical institution must return the payment in a timely manner according to the agreement, and must not be in arrears.

After the purchase and sale agreement is signed, the medical institution and the selected enterprise shall not enter into other agreements that deviate from the substantive content of the agreement, or make any interest requirements other than the agreement.

Declaring companies need to be approved by the State Drug Administration, obtain a valid medical device (drug) production license and medical device registration certificate, and have no record of major violations in business activities in the three years prior to participating in this procurement activity.

In 2020, medical consumables (drugs) manufacturers (imported and Hong Kong, Macao and Taiwan products imported and Hong Kong, Macao and Taiwan products) in public medical institutions that have sales records in the Hengyang area (can be extended to Hunan Province) have sales records and are included in the scope of this procurement The only general agent in the region, the authorized distribution period for imported and Hong Kong, Macao and Taiwan products must cover the entire procurement cycle).

All the non-selected products are included in the monitoring and management, and they are not allowed to be sold in public medical institutions during the centralized procurement cycle. This may be a serious blow to the companies that are not selected this time. A total of 8 varieties were carried this time, and the total pre-purchasing volume in 2021 will be 3,988,000.

02

Domestic and imported separately

In terms of procurement varieties and agreed procurement quantities, the dialyzers are divided into two categories: domestic (including foreign brands produced in China) and imported according to the medical device registration certificate.

Two low-pass and two high-pass are selected from domestic products, and one low-pass (or mid-pass) and one high-pass are selected from imported products (only used to solve the allergic reaction of individual patients); low calcium peritoneal dialysate and peritoneal dialysate 2 domestic products (including foreign brands produced in China) selected from each;

The remaining products are domestically produced (including foreign brands produced in China), 2 are selected, and 1 is imported (no imported products are not selected).

When the same product of the same company has multiple specifications, the company independently selects and determines one of the products as a representative product to participate in the review. In principle, the representative product is the company's product with the best technological advancement, quality reliability, and comprehensive cost-effectiveness. The product.

Declaring companies make quotations based on different products, and each company can only quote one price per product.

The ranking is determined according to the declared price of the product, the lowest declared price is the first, the second lowest is the second, and so on. In the case of the same declared price, the ranking shall be determined in sequence according to the following rules: the priority is given to providing more varieties or specifications; if the variety and specifications are still the same, the first registration certificate of the quotation product is given priority.

03

Lowest price is not the only condition

The rules are more detailed in terms of product selection and selection:

The dialyzers are divided into two categories: domestic products (including foreign brands produced in China) and imported products. Two low-pass and two high-pass products will be selected for domestic products, and one imported product (only used to solve the allergic reactions of individual patients) will be selected. Low-pass (or mid-pass), 1 Qualcomm; other domestic products (including foreign brands produced in China) are planned to be selected 2 products, and imported products are planned to be selected 1 (no imported products are not selected).

In the same quotation group, if the person in charge is the same person, or there is a direct holding or management relationship, it is regarded as the same enterprise, and each company can only quote one price per bid group.

For products in the same quotation group, the actual applying companies that meet the application qualifications shall determine the quotation finalists according to their effective quotations from low to high. The rule is: after passing the qualification review and technical review, from the first round of quotation (quotation when submitting materials), The shortlisted companies and products are selected according to the ratio of 1:3 of the number of products to be selected.

After the enterprise's declared products are shortlisted, the second round of bidding will be conducted. The second round of quotations must be lower than the first round of shortlisted quotations, and the selected varieties and prices will be comprehensively evaluated based on the second round of quotations and other scoring indicators.

In the scoring standard, the comprehensive scoring method is adopted, and the lowest price cannot be the only condition for selection. Each variety is divided into domestic and imported groups and the comprehensive scores are sorted from high to low.

Product unit price score accounted for 45 points, price reduction score accounted for 45 points, and market share score accounted for 10 points. The prices are ranked from low to high. The average price of the previous four final quotations is used as the evaluation benchmark price, and the one that is lower than the evaluation benchmark price is full marks.

The product unit price points of other bidders are uniformly calculated according to the following formula: product unit price points = (assessment base price/final quotation) × 45% × 100; scoring rules for reduction points: the price of each bid product is listed on the Hunan platform and the Hengyang area The lower value of the actual transaction price of public medical institutions is the basic price, and the rate of decrease is divided into (basic price-quotation)/basic price × 45% × 100;

The market share scoring rules: According to the sales records of public medical institutions in the Hengyang region in 2020 (the bidding companies need to provide basis), each hospital will get 2 points, and the maximum is no more than 10 points. According to the comprehensive evaluation results, the same evaluation product is divided into the first selected candidate, followed by the second selected candidate, and so on.

The declared price of each product to be selected in the second round shall be the price of the product to be selected.

It can be seen that in the post-epidemic era, hierarchical diagnosis and treatment and the sinking of medical resources have become a fait accompli. The configuration and procurement of medical equipment is one of the key tasks. The basic requirements are: there must be equipment vacancies to be filled as soon as possible, obsolete and backward. Timely update;

In this process, domestic medical equipment has become the first choice for many provinces, and the scene of domestic brands and international giants "fighting bayonet" has become clear, and it has reached a critical moment of no compromise.